ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0286

Online CME Successful at Improving Nephrologist Understanding of Emerging Class to Treat Anemia Associated with CKD

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Larkin, Amy, Medscape LLC, New York, New York, United States
  • Anderson, David R., Medscape LLC, New York, New York, United States
  • Boutsalis, George, Medscape LLC, New York, New York, United States

As emerging therapies hold promise to improve treatment of anemia in patients with CKD, clinicians need to understand mechanisms of action in order to understand the potential place in therapy when available. We sought to determine if online continuing medical education (CME) could improve the clinical knowledge of nephrologist related to emerging Hypoxia-Inducible Factor Prolyl Hyproxylase Inhibitors (HIF-PHIs).


The effect of an online, CME-certified, roundtable video discussion was analyzed to determine efficacy of online education. Three multiple-choice knowledge/competence questions and 1 self-efficacy confidence question were presented both before and immediately after each activity. A repeated pairs pre-/post-assessment study design was used and McNemar’s chi-squared test (5% significance level, P <.05) assessed educational effect. Cramer's V was used to calculate the effect size (0.06-0.15 is a noticeable effect, 0.16-0.26 considerable, and >0.26 extensive). The activity launched June 27, 2019 and data were collected through August 27, 2019.


In total, 62 nephrologists answered all pre-/post-assessment questions and were included in the study.

Overall improvements were seen after participation in both CME activities:
24% of nephrologists (P<.05; V=.216) improved at correctly identifying the mechanism of action of HIF-PHIs
11% of nephrologists (P=.72; V=.032) demonstrated improvement at selecting the recommended use of erythropoiesis stimulating agents (ESAs) in the treatment of anemia
21% of nephrologists (P<.05; V=.181) improved at recognizing clinical trial data of HIF-PHIs
47% reported increased confidence in understanding of HIF stabilizers in the treatment of anemia in patients with CKD
Continued educational gaps:
52% of nephrologists did not recognize the mechanism of action of emerging HIF-PHIs
47% of nephrologists did not recognize the role of ESAs in the treatment of anemia
31% of nephrologists did not recognize clinical trial data for emerging HIF-PHIs


This study demonstrates the success of online, video-based roundtable discussion on improving knowledge of nephrologists related to emerging treatments for anemia associated with CKD. Continued knowledge gaps were identified for future educational targets.


  • Commercial Support